Hyperbilirubinemia modulates myocardial function, aortic ejection, and ischemic stress resistance in the Gunn rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 8, 2014, Pages H1142-H1149

  Bakrania, Bhavisha ^a   Toit, Eugene F Du ^a   Ashton, Kevin J ^b   Kiessling, Can J ^b   Wagner, Karl Heinz ^a,c   Headrick, John P ^a   Bulmer, Andrew C ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b BOND UNIVERSITY   (Australia)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bilirubin; Gilbert s syndrome; Ischemia reperfusion; Ischemic heart disease; Myocardium; Vascular function

Indexed keywords

BILIRUBIN; GLUTATHIONE PEROXIDASE; PHOSPHOLAMBAN; SUPEROXIDE DISMUTASE; CALCIUM BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; GENE EXPRESSION; GUNN RAT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HYPERBILIRUBINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PRESSURE GRADIENT; RAT; STRESS; ANIMAL; AORTA; BLOOD; BLOOD FLOW VELOCITY; BLOOD PRESSURE; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; METABOLISM; PATHOPHYSIOLOGY; REPERFUSION INJURY; VASODILATATION;

ANIMALS; AORTA; BILIRUBIN; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; HEART VENTRICLES; HYPERBILIRUBINEMIA; MYOCARDIAL CONTRACTION; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, GUNN; STROKE VOLUME; SUPEROXIDE DISMUTASE; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 84908108571     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00001.2014     Document Type: Article

References (40)

1. Adin C, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 288: F778-F784, 2005.
2. Ashton KJ, Tupicoff A, Williams-Pritchard G, Kiessling CJ, See Hoe LE, Headrick JP, Peart JN. Unique transcriptional profile of sustained ligand-activated preconditioning in pre-and post-ischemic myocardium. PLOS ONE 8: e72278, 2013.
3. Ben-Amotz R, Bonagura J, Velayutham M, Hamlin R, Burns P, Adin C. Intraperitoneal bilirubin administration decreases infarct area in a rat coronary ischemia/reperfusion model. Front Physiol 5: 53, 2014.
4. Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol 307: F123-F136, 2014.
5. Boon AC, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner KH, Bulmer AC. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 52: 2120-2127, 2012.
6. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, De Boer A, Oostra a B, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171-1175, 1995.
7. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199: 390-396, 2008.
8. Bulmer AC, Coombes JC, Blanchfield JT, Toth I, Fassett RG, Taylor SM. Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. Br J Pharmacol 164: 1857-1870, 2011.
9. Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res 52: 193-205, 2013.
10. Ceran C, Sonmez K, Turkyilmaz Z, Demirogullari B, Dursun A, Duzgun E, Basaklar AC, Kale N. Effect of bilirubin in ischemia/ reperfusion injury on rat small intestine. J Pediatr Surg 36: 1764-1767, 2001.
11. Chan GM, Ash KO, Hentschel W, Wu J. Effects of bilirubin on ionized calcium. Clin Chem 27: 204-205, 2001.
12. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 278: H643-H651, 2000.
13. - activity in SH-SY5Y cells by unconjugated bilirubin. PLOS ONE 6: e29078, 2011.
14. Iyanagi T, Watanabe T, Uchiyama Y. The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a -1 frameshift mutation. J Biol Chem 264: 21302-21307, 1989.
15. Kalkan GY, Gür M, Baykan AO, Koyunsever NY, Kaypakli O, Sen O, Kuloglu O, Seker T, Uçar H, Akyol S, Elbasan Z, Sahin DY, Cayli M. Serum bilirubin level and aortic intima-media thickness in patients without clinical manifestation of atherosclerotic cardiovascular disease. Angiology 65: 308-312, 2014.
16. Lumlertgul D, Boonyaprapa S, Bunnachak D, Thanachaikun N, Praisontarangkul O, Phornphutkul K, Keoplung M. The jaundiced heart: evidence of blunted response to positive inotropic stimulation. Ren Fail 13: 15-22, 1991.
17. Malik SG, Irwanto KA, Ostrow JD, Tiribelli C. Effect of bilirubin on cytochrome c oxidase activity of mitochondria from mouse brain and liver. BMC Res Notes 3: 162, 2010.
18. Matés JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153: 83-104, 2000.
19. Mazzone GL, Rigato I, Tiribelli C. Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. Biosci Trends 4: 244-248, 2010.
20. -/- mice and the Gunn rat. Am J Physiol Heart Circ Physiol 293: H333-H342, 2007.
21. Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett 331: 281-284, 1993.
22. Novotný L, Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 228: 568-571, 2003.
23. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, Csizmadia E, Graça-Souza AV, Liloia A, Soares MP, Otterbein LE, Usheva A, Yamashita K, Bach FH. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112: 1030-1039, 2005.
24. Peyton KJ, Shebib AR, Azam M, Liu XM, Tulis D, Durante W. Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front Pharmacol 3: 48, 2012.
25. Qaisiya M, Coda Zabetta CD, Bellarosa C, Tiribelli C. Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway. Cell Signal 26: 512-520, 2014.
26. Reicheilt ME, Willems L, Peart JN, Ashton KJ, Martherne GP, Blackburn MR, Headrick JP. Modulation of ischaemic contracture in mouse hearts; a "supraphysiological" approach to adenosine. Exp Physiol 92: 175-185, 2007.
27. 2-adrenergic receptor is associated with reduced phospholamban protein. J Clin Invest 97: 1618-1623, 1996.
28. Shaia WT, Shapiro SM, Hellar AJ, Galiani DL, Sismanis A, Spencer RF. Immunohistochemical localization of calcium-binding proteins in the brainstem vestibular nuclei of the jaundiced Gunn rat. Hear Res 173: 82-90, 2002.
29. Stec DE, Storm MV, Pruett BE, Gousset MU. Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition. Am J Hypertens 26: 918-923, 2013.
30. Strassburg CP. Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? Drug Metab Rev 42: 168-181, 2010.
31. Sumandea MP, Steinberg SF. Redox signaling and cardiac sarcomeres. J Biol Chem 286: 9921-9927, 2011.
32. Trost GR, Nagatani K, Goknur AB, Haworth RA, Odell GB, Duff TA. Bilirubin levels in subarachnoid clot and effects on canine arterial smooth muscle cells. Stroke 24: 1241-1245, 1993.
33. Vera T, Granger JP, Stec DE, Regul JP. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol 297: R738-R743, 2009.
34. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny L, Kotal P. Gilbert's syndrome and ischaemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160: 449-456, 2000.
35. Vitek Novotny L, Sperl M, Holaj R, Spacil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21: 408-414, 2006.
36. Wallner M, Antl N, Rittmannsberger B, Schreidl S, Najafi K, Müllner E, Mölzer C, Ferk F, Knasmüller S, Marculescu R, Doberer D, Poulsen H, Vitek L, Bulmer A, Wagner KH. Anti-genotoxic potential of bilirubin in vivo: damage to DNA in hyperbilirubinemic human and animal models. Cancer Prev Res (Phila) 6: 1056-1063, 2013.
37. Wallner M, Bulmer AC, Mölzer C, Müllner E, Marculescu R, Doberer D, Wolzt M, Wagner OF, Wagner KH. Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome. Eur J Clin Invest 43: 912-919, 2013.
38. Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxide in cultured cells and tissue. Nat Prot 5: 51-66, 2010.
39. Yu QY, Shu M, Dai JH, Ma J, Yu YH. [The mechanism of the increase of plasma bilirubin after hepatic ischemia-reperfusion in rats]. Zhonghua Gan Zag Bing Za Zhi 10: 763-766, 2007.
40. Zelenka J, Lenicek M, Muchova L, Jirsa M, Kudla M, Balaz P, Zadinova M, Ostrow J, Wong R, Vitek L. Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 867: 37-42, 2008.